论文部分内容阅读
目的:分析研究三阴性乳腺癌采取临床化疗治疗的临床效果以及预后。方法:抽取2012年11月-2014年2月在我院收治的患有乳腺癌的病人100例,其中,根据根据免疫组化法筛选ER(雌激素受体)、PR(孕激素受体)、Her-2(人表皮生长因子受体2)全部为阴性的三阴性乳腺癌23例,作为实验组;另外,非三阴性乳腺癌病人77例,作为对照组,对两组病人均实施临床化疗给予治疗,对其临床治疗效果以及预后给予对比分析。结果:实验组临床治疗总体有效率为56.5%,对照组临床治疗总体有效率33.7%,可是中位肿瘤进展时间低于对照组,两组间差异具有统计学意义(P<0.05)。结论:三阴性乳腺癌采取临床化疗治疗,可以获得良好的治疗,可是无法逆转患者预后较差的转归。
Objective: To analyze the clinical efficacy and prognosis of triple negative breast cancer treated with clinical chemotherapy. METHODS: A total of 100 patients with breast cancer who were admitted to our hospital from November 2012 to February 2014 were selected. Among them, ER (estrogen receptor) and PR (progesterone receptor) were screened according to the immunohistochemical method. Twenty-three triple-negative breast cancers with Her-2 (human epidermal growth factor receptor 2) negative were used as the experimental group; 77 non-triple negative breast cancer patients were used as the control group and clinically performed on both groups of patients. Chemotherapy was given for treatment, and its clinical treatment effect and prognosis were compared and analyzed. Results: The total effective rate of clinical treatment was 56.5% in the experimental group and 33.7% in the control group, but the median tumor progression time was lower than the control group. There was a statistically significant difference between the two groups (P<0.05). Conclusion: The clinical treatment of triple-negative breast cancer can achieve good treatment, but it can not reverse the prognosis of patients with poor prognosis.